Marcia S Brose

9PUBLICATIONS
31CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2026
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.

|Apr 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.

Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan

|Aug 02, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

Lori J Wirth, Marcia S Brose, Vivek Subbiah

|Jun 03, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.

Marcia S Brose, Jaume Capdevila, Rossella Elisei

|Sep 28, 2023
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors.

Marcia S Brose, David S Hong, Alexander Drilon

|Jan 06, 2023
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.

Vicky Makker, Carol Aghajanian, Allen L Cohn

Pageof 2

Frequent Collaborators

3 joint publications

Lori J Wirth

3 joint publications

Alexander Drilon

2 joint publications

Vivek Subbiah

1 joint publications

Eric J Sherman